Oncopeptides AB (ONCO) — Working Capital to Net Assets Ratio
Oncopeptides AB (ONCO) has a Working Capital to Net Assets ratio of -123.4% as of December 2025. Working capital of Skr72.66 Million (current assets of Skr117.16 Million minus current liabilities of Skr44.50 Million) is measured against net assets of Skr-58.89 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Oncopeptides AB net asset quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Oncopeptides AB Working Capital to Net Assets (2014–2025)
This chart shows how Oncopeptides AB's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of December 2025, the ratio stands at -123.4%, reflecting working capital of Skr72.66 Million against net assets of Skr-58.89 Million SEK. Check tangible equity quality of Oncopeptides AB to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Oncopeptides AB (2014–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Oncopeptides AB from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see ONCO stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -123.4% | Skr72.66 Million | Skr-58.89 Million | Skr117.16 Million | Skr44.50 Million | ▼ -428.7 pp |
| 2024 | 305.3% | Skr165.73 Million | Skr54.28 Million | Skr217.08 Million | Skr51.35 Million | ▲ +27.1 pp |
| 2023 | 278.2% | Skr157.97 Million | Skr56.78 Million | Skr202.90 Million | Skr44.93 Million | ▲ +183.6 pp |
| 2022 | 94.6% | Skr278.36 Million | Skr294.29 Million | Skr364.03 Million | Skr85.67 Million | ▲ +5.9 pp |
| 2021 | 88.7% | Skr187.08 Million | Skr210.87 Million | Skr412.37 Million | Skr225.29 Million | ▼ -5.0 pp |
| 2020 | 93.7% | Skr540.40 Million | Skr576.90 Million | Skr894.80 Million | Skr354.40 Million | ▼ -7.4 pp |
| 2019 | 101.1% | Skr805.71 Million | Skr797.01 Million | Skr970.89 Million | Skr165.18 Million | ▼ -2.6 pp |
| 2018 | 103.7% | Skr327.48 Million | Skr315.83 Million | Skr441.32 Million | Skr113.84 Million | ▲ +3.9 pp |
| 2017 | 99.8% | Skr417.23 Million | Skr418.00 Million | Skr477.22 Million | Skr59.99 Million | ▲ +5.0 pp |
| 2016 | 94.8% | Skr24.97 Million | Skr26.34 Million | Skr54.27 Million | Skr29.30 Million | ▼ -11.8 pp |
| 2015 | 106.6% | Skr-2.77 Million | Skr-2.60 Million | Skr4.23 Million | Skr7.00 Million | ▲ +8.9 pp |
| 2014 | 97.7% | Skr7.43 Million | Skr7.61 Million | Skr12.94 Million | Skr5.52 Million | — |